Introduction
Type I diabetes is a metabolic disease secondary to destruction of the insulin-producing cells of the pancreas, most likely by an autoimmune mechanism. However, at the time of diagnosis, at least in some patients, not all insulinproducing cells are destroyed and there is a theoretical possibility that elimination of the mechanism causing this destruction would allow the remaining cells to secure independence from exogenous insulin. In fact, it has recently been shown by Voltarelli et al. 1 that the clinical course of this disease could be modified by immune ablation and PBSCT. A more recent publication summarizes follow-up outcomes for altogether 20 patients, of whom 12 remain exogenous insulin-free for a mean 31 months. 2 No life-threatening complications were observed in these patients during the transplantation procedure or post-transplantation observation.
In this report we describe the effects of this treatment modality in an independent series of cases.
Patients and methods
Since March 2008 all new type I diabetes patients diagnosed at or referred to the Department of Internal Diseases, Diabetology and Endocrinology, Central Hospital, Ministry of Interior Affairs and Administration, Warsaw, Poland, and who fulfilled specific criteria were informed about the availability of this possible treatment. Patients interested in participating were interviewed by the physician and all possible risks of the procedure were carefully explained. The specific criteria included age of 12-35 years, time from the initial diagnosis of type I diabetes to beginning of treatment no longer than 6 weeks, confirmed presence of glutamic acid decarboxylase antibodies, C-peptide presence in serum, World Health Organization performance status of patients p2, compliance with general guidelines and modifications of lifestyle before and after transplantation (diet, physical activity, avoidance of infection risk), and written consent signed before the procedure. The exclusion criteria were ketoacid diabetic coma in patients medical history, use of high-dose steroids in the pretransplantation period, presence of other diseases that excluded immunosuppressive treatment, active viral and bacterial infections, liver diseases (cirrhosis or hepatitis) and kidney diseases (glomerular filtration rate o60 mL/min), asthma or other severe allergic diseases, pregnancy, or other diseases that could potentially influence the transplantation outcome.
The protocol was initiated in the spring of 2008 after approval as a therapeutic option by the Bioethics Committee of the Medical University of Warsaw. Patients who fulfilled the criteria were offered the treatment as the therapeutic possibility. They were then interviewed and signed informed consent if they agreed. After the exclusion of pregnant women, patients were given an oral contraceptive. The possibility of banking semen was also offered to all men in the study.
Plasmapheresis
Treatment started with two to three plasmaphereses, which were performed to remove circulating antibodies and immunological complexes. The serum was exchanged for albumin.
Mobilization
Patients received CY 2 g/m 2 divided into two doses with a 12-h interval. Mesna (sodium 2-mercaptoethanesulfonate) (4 g/m 2 in 24-h infusion) and proper hydration were used as prophylaxis for hemorrhagic cystitis. G-CSF, at a dose of 10 mg/kg/day, was administered from the day after CY infusion. Leukapheresis was started when CD34 þ cell count in the peripheral blood was 410 per mL and was continued until 43.0 Â 10 6 CD34 þ cells per kg of body weight were collected. The cells were frozen and stored according to standard protocols of our centre.
Conditioning
CY 50 mg/kg once daily in 1-h i.v. infusion was administered on days -5, -4, -3 and -2 before stem cell infusion (total dose 200 mg/kg). Mesna and proper hydration were used as prophylaxis for hemorrhagic cystitis. Anti-thymocyte globulin (ATG, Genzyme Corporation, Cambridge, MA, USA) was given at doses of 0.5 mg/kg on day À5 and 1 mg/kg/day on days -4, -3, -2 and -1 before transplantation in 5-h infusions (total dose 4.5 mg/kg). The patients received cetirizine (2 Â 10 mg) as a prophylaxis for allergic reactions to ATG. The stem cells were given on day 0. The G-CSF was started on day þ 5 after the transplantation at a dose of 5 mg/kg and was continued until neutrophil count was 41000 per mL.
Infection prophylaxis
The patients were hospitalized in the intensive care unit of the Hematology Department. Prophylactic antibiotics were not given. Fluconazole, acyclovir and cotrimoxazole were given as infection prophylaxis and were continued up to 60 days after the transplantation (acyclovir up to 35 days after the transplantation). Patients were monitored for CMV by PCR once weekly for up to 60 days after the transplantation.
Results
Between March 2008 and May 2009, 19 patients were referred for assessment and possible enrollment. Eleven patients refused and eight consented to immunoablation and transplantation. The mean age of patients was 25.8 (range 19-32) years. Seven out of eight patients exhibited typical symptoms of diabetes at diagnosis (polydypsia, polyuria, weight loss). One patient had abnormal levels of glucose in an accidentally performed test and was later diagnosed to have type I diabetes. The basic demographic data are shown in Table 1 . The HLAs characteristic for diabetes were present in all patients-with the most common being DRB1 *04, seen in seven out of eight patients. [3] [4] [5] [6] One patient had four HLAs, one had three Ags and six patients had two Ags associated with type I diabetes. Two patients developed other autoimmune disorders at the onset of diabetes (vitiligo and autoimmune thyroiditis). Mean time from diagnosis to transplantation was 60 days (from 55 to 74 days). The mean hospital stay was 39 days (from plasmapheresis to discharge after transplantation, range 36-45 days). Patients received on average 4.14 Â 10 6 per kg of CD34 þ cells. Patients that mobilized high numbers of CD34 þ cells, exceeding the numbers needed for a single transplantation, had the cells stored for eventual future use. Engraftment, with a neutrophil count 4500 per mL, was seen on average 10 days after the transplantation (range 9-13 days). Platelet engraftment (420 000 per mL) occurred on average on day 10 (range 7-14 days). There were no major complications during treatment. All patients experienced nausea and moderate fever during the conditioning. Febrile neutropenias were treated with wide-spectrum antibiotics and blood cultures remained negative. Patient number 3 experienced an elevation of transaminase activity in the blood 7 months after the transplantation, which resolved after a switch from acarbose to small doses of insulin (0.07 IU/kg).
All patients became independent of exogenous insulin after the transplantation. The exogenous insulin administration was ceased on day þ 24 after the transplantation on an average (range 6-60 days) ( Table 2 (Figure 1 ). The initial insulin requirement did not correlate with time of insulin independence. To additionally improve glycemic control, patients received acarbose-starting from a dose of 3 Â 100 mg, and later adjusted to the needs of the patient. This treatment was continued in the post-transplantation period in a majority of the patients (six out of eight patients). The mean glycated hemoglobin was 12.33% at diagnosis. During the observation, the mean numbers were 5.59 and 6.23% at 3 and 6 months after the transplantation, respectively. The C-peptide levels varied greatly among patients. It was usually low at diagnosis, showing a rise at the time of transplantation and lowered afterwards, however, usually to levels higher than were seen at diagnosis ( Table 2) . As of November 2009, seven of eight patients remain normoglycemic without the need for exogenous insulin with a mean follow-up of 7 months.
Discussion
Our data show that immunoablation and reconstitution of the immune system with autologous PBSCs can restore Immunoablation and BMT in newly diagnosed type I diabetes E Snarski et al independence from exogenous insulin in early type I diabetes. The results are similar to the ones reported by Voltarelli et al. 1 Although this report confirms that immunoablation at least temporarily inhibits the mechanism that destroys b-cells, which is responsible for type I diabetes, and that this modality is of significant clinical value, it is still unclear whether the method used in reported patients is optimal. First, it is possible that immunoablation alone without stem cell mobilization, collection and transplantation would be sufficient. 7 Second, there are possible modifications for the immunoablative procedure such as inclusion of monoclonal antibodies that may improve its efficiency. Data reported from this series of cases provide an essential argument to initiate such a trial that would verify Voltarelli et al.
1 and current data.
There have been significant safety concerns as type I diabetes is a chronic disease with significant complications, but without risk of early mortality if treated with insulin. On the other hand, immunoablation and auto-SCT is associated with a greater risk. However, it has been minimized in recent years 8 and considered justified in several other autoimmune disorders. Moreover, diabetic patients differ from patients with hematological malignancies, who have standard indications for this procedure, in that they do not have disease affecting hematopoiesis, therefore their hematopoietic recovery should be rapid. From this point of view, immunoablation associated with transplantation could be a safer procedure than immunoablation alone as it shortens time to hematopoietic recovery.
Another open question is to what extent are the results influenced by spontaneous remissions. We will never be able to identify patients who are in spontaneous remission. However, as mentioned, in parallel to patients who consented to the procedure and were treated, there were patients who did not consent. None of these latter cases had reached spontaneous remission nor become at least temporarily independent of exogenous insulin.
Our protocol was slightly modified when compared with Voltarelli's group in order to address two important issues of diabetes treatment. First, the presence of autoantibodies of proven toxicity to b-cells, and second, the loss of b-cells before treatment that possibly resulted in a type II diabeteslike condition in patients with inadequate insulin production. The plasmaphereses were directed toward reducing the influence of antibodies and immune complexes toxic to b-cells on the outcome of the transplantation. The addition of plasmaphereses to the protocol was based on the observation that plasmapheresis alone can modify the clinical course of diabetes. 9 The various oral antidiabetic drugs were shown to prevent the development of type II diabetes in susceptible individuals. We chose acarbose as an inexpensive and safe drug, which was shown to protect b-cell function and potentially prevent the development of type II diabetes; or in case of our patients, progression of type I diabetes. 10 The Voltarelli's group used sitagliptin-a dipeptidyl peptidase-4 inhibitor-in transplanted patients who reverted to exogenous insulin use. The use of this oral drug led to the recovery of insulin independence in some of the patients. 11 The oral drug that might bring the most benefit for transplanted patients has yet to be identified. Immunoablation and BMT in newly diagnosed type I diabetes E Snarski et al
Transplantation of autologous hematopoietic cells is a relatively safe procedure; however, the possible side effects of the transplantation are a serious concern for the enrolled diabetic patients. The mortality of o1%, which can be expected during this procedure, might justify the use of this procedure in fatal autoimmune diseases. On the other hand, for patients with diabetes, it might just be too high of a risk. Most of the patients who did not agree to take part in the study were afraid of the possibility of death caused by the treatment. So far we have not observed any serious complications in our group of patients. Long-term complications, such as an increased risk of tumors, were usually less relevant in the patients' decision-making. However, the short-and long-term risks of transplantation should be compared with the short-and long-term complications of diabetes.
To our knowledge, this is the second report of immunoablation followed by auto-SCT in the treatment of early type I diabetes. We were able to modify the course of disease and in all patients, inducing at least temporary remission of type I diabetes. Further observation and multicentre clinical trials are needed to verify the extent to which this approach could provide long-term remission of type I diabetes. 
